Latest Biotech News

Revolution Medicines’ pancreatic cancer drug Rasonque drew fresh scrutiny after FDA review documents and new dataset readouts suggested narrower performance than investors had assumed. In trading,...

The FDA approved atezolizumab with chemotherapy as adjuvant treatment for stage III dMMR colon cancer following the phase III ATOMIC trial. The decision follows results indicating a 50% reduction...

Matchpoint Therapeutics secured a $150 million Series B to advance an oral covalent small-molecule pipeline targeting autoimmune and inflammatory diseases. The financing expands resources for...

TRex Bio priced a $117 million IPO on the Nasdaq to fund development of immune therapies focused on regulatory T cells. The company’s lead program, TRB-061, is a fusion protein targeting TNFR2 on...

A phase II pilot trial reported that a single fecal microbiota transplantation combined with atezolizumab and bevacizumab was safe and produced tumor responses in about one third of liver cancer...

ARPA-H moved forward with BioStabilization Systems (BoSS) under its BioStabilization Systems program by funding Phase I work aimed at enabling room-temperature stabilization of cell-based...

The Journal of Pharmaceutical Investigation announced a January 2027 special issue focused on translational advances in pharmaceutical dosage form development, centered on particle engineering and...

Researchers combined anti-PD-L1 immunotherapy with the PARP inhibitor olaparib to trigger ferroptosis in liver cancer and used a SLC7A11-targeted F-18 PET tracer (F-18 FASu) to visualize treatment...

A study reported that stress-responsive MAIT cells can promote an immunosuppressive peritumoral environment and drive microvascular invasion in hepatocellular carcinoma through the CCL20–CCR6...

A Nature Reviews Clinical Oncology review proposed a modular biomarker framework for antibody–drug conjugates that goes beyond semi-quantitative immunohistochemistry. The paper emphasizes...

FDA approved atezolizumab plus chemotherapy for adjuvant treatment of stage III dMMR colon cancer after the phase 3 ATOMIC trial met its primary endpoint. The company said the regimen cut the risk...

TRex Bio priced its $117 million IPO to advance immune-modulating therapies built to activate regulatory T cells (Tregs). The company sold 8.33 million shares at $14 each and begins trading on...

Viatris agreed to acquire Pacira BioSciences for about $1.65 billion, adding commercial-stage non-opioid pain assets to its portfolio. The deal is structured as a cash transaction and comes as...

Matchpoint Therapeutics closed a $150 million Series B to push its pipeline of oral covalent small molecules for autoimmune and inflammatory diseases. The financing supports advancement toward...

A randomized phase 2a trial found that monoclonal antibody AER002 is safe but ineffective for Long COVID overall. Investigators reported that post-hoc analyses pointed to potential benefit in a...

EsoBiotec provided extended follow-up for in vivo BCMA CAR-T therapy ESO-T01 in relapsed or refractory multiple myeloma. Updated data through a maximum 15-month follow-up showed an objective...

Vitalize secured a $31 million Series A to help hospitals manage labor and capacity, positioning the startup to compete in operational optimization tooling for healthcare providers. The round was...

The SEC and FDA moved to formalize cooperation through a memorandum of understanding that tightens disclosure rules for pharmaceutical companies. The MOU establishes structured information-sharing...

Roche is shifting beyond licensing by partnering with Chinese startup Defand Therapeutics to discover new medicines. The collaboration marks a continuation of pharma’s China push, but with a...

ARPA-H launched BioStabilization Systems (BoSS) funding to address the cold-chain barrier for cell-based biologics. ARPA-H committed up to $87 million across the program’s four-year timeline, with...